Pharmacokinetic evaluation of long-term Xolair-therapy in severe asthma patients

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON25198

Enrollment

Registered

2019-06-06

Start date

2019-06-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic Asthma

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Severe asthma patients, receiving more than 12 months of omalizumab therapy, >18 months old, able to sign informed consent.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
The percentage of patients with a ratio omalizumab trough-level to baseline IgE larger than 15:1	—

Secondary

Measure	Time frame
Association of the ratio omalizumab trough-level to baseline IgE and patients yearn for the next gift Association of the ratio omalizumab trough-level to baseline IgE and asthma-related outcomes (ACQ, AQLQ, FEV1, NO)	—

Contacts

Public ContactHans Kroes

Medisch Centrum Leeuwarden

hans.kroes1@znb.nl0582861837

Outcome results